Universal access to quality medicines: prioritisation of a-priori solutions [letter]

T.P.C. Dorlo; M. Boelaert; J.H. Beijnen; R. Ravinetto

doi:10.1016/S1473-3099(12)70259-1

Universal access to quality medicines: prioritisation of a-priori solutions [letter]

T.P.C. Dorlo, M. Boelaert, J.H. Beijnen, R. Ravinetto

Clinical Trial Centre

Research output: Contribution to journal › Letter › peer-review

Original language	English
Journal	Lancet Infectious Diseases
Volume	12
Issue number	11
Pages (from-to)	829-830
Number of pages	2
ISSN	1473-3099
DOIs	https://doi.org/10.1016/S1473-3099(12)70259-1
Publication status	Published - 2012

Keywords

Health systems
Drug supply
Drug availability
Accessibility
Quality assurance
Priorities
Counterfeit drugs
Substandard drugs
Quality control
Governance
National policies
Detection
Global

Access to Document

10.1016/S1473-3099(12)70259-1

http://lib.itg.be/pdf/itg/2012/2012lanc0829.pdf

Cite this

@article{4ac284efbcc24ce682cd3e11add974dc,

title = "Universal access to quality medicines: prioritisation of a-priori solutions [letter]",

keywords = "Health systems, Drug supply, Drug availability, Accessibility, Quality assurance, Priorities, Counterfeit drugs, Substandard drugs, Quality control, Governance, National policies, Detection, Global",

author = "T.P.C. Dorlo and M. Boelaert and J.H. Beijnen and R. Ravinetto",

note = "NPP; ITG-H2A; ITG-CLA; MULTI; DPH; DCS; U-ECTD; U-CTU; JIF; DOI; PDF; DSPACE",

year = "2012",

doi = "10.1016/S1473-3099(12)70259-1",

language = "English",

volume = "12",

pages = "829--830",

journal = "Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Universal access to quality medicines: prioritisation of a-priori solutions [letter]

AU - Dorlo, T.P.C.

AU - Boelaert, M.

AU - Beijnen, J.H.

AU - Ravinetto, R.

N1 - NPP; ITG-H2A; ITG-CLA; MULTI; DPH; DCS; U-ECTD; U-CTU; JIF; DOI; PDF; DSPACE

PY - 2012

Y1 - 2012

KW - Health systems

KW - Drug supply

KW - Drug availability

KW - Accessibility

KW - Quality assurance

KW - Priorities

KW - Counterfeit drugs

KW - Substandard drugs

KW - Quality control

KW - Governance

KW - National policies

KW - Detection

KW - Global

U2 - 10.1016/S1473-3099(12)70259-1

DO - 10.1016/S1473-3099(12)70259-1

M3 - Letter

C2 - 23099080

SN - 1473-3099

VL - 12

SP - 829

EP - 830

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

IS - 11

ER -